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Dependence receptors now number more than a 
dozen,  including  deleted  in  colorectal  cancer 
(DCC) (1), UNC5H (2), Patched (3), some inte-
grins (4), neogenin (5), p75NTR (6), RET (7), 
ALK (8), and TrkC (9). Although they have no 
structural homology (other than possibly in a do-
main referred to as the DART [dependence-asso-
ciated  receptor  transmembrane]  domain)  (10), 
they all share the functional property of inducing 
cell death when disengaged from their trophic li-
gands, whereas the presence of their trophic li-
gands blocks this proapoptotic activity. Such 
receptors thus create cellular states of dependence 
on their respective ligands (11, 12).
The prototype dependence receptors are the 
netrin-1 receptors. Netrin-1, a diffusible lam-
inin-related protein, has been shown to play a 
major role in the control of neuronal navigation 
during the development of the nervous system 
by interacting with its main receptors, DCC (13, 
14, 15) and UNC5H (16, 17). However, DCC 
and  UNC5H  (i.e.,  UNC5H1,  UNC5H2, 
UNC5H3, and UNC5H4) have been shown to 
belong to the dependence receptor family (1, 2). 
This dependence effect upon netrin-1 has been 
suggested to act as a mechanism for eliminating 
tumor cells that would develop in settings of li-
gand unavailability (for reviews see references 18, 
19). Along this line, disruption of the proapop-
totic signaling of these netrin-1 receptors in the 
gastrointestinal tracts of mice, by netrin-1 overex-
pression or by inactivation of UNC5H3, is asso-
ciated with intestinal tumor progression (20, 21).
Thus, loss of the dependence receptors’ pro-
apoptotic activity represents a selective advan-
tage for tumor cells. In this respect, DCC was 
proposed in the early 1990s to function as a tu-
mor suppressor gene, whose expression is lost in 
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Neuroblastoma (NB), the most frequent solid tumor of early childhood, is diagnosed as a 
disseminated disease in >60% of cases, and several lines of evidence support the resistance to 
apoptosis as a prerequisite for NB progression. We show that autocrine production of netrin-1, 
a multifunctional laminin-related molecule, conveys a selective advantage in tumor growth 
and dissemination in aggressive NB, as it blocks the proapoptotic activity of the UNC5H 
netrin-1 dependence receptors. We show that such netrin-1 up-regulation is a potential 
marker for poor prognosis in stage 4S and, more generally, in NB stage 4 diagnosed infants. 
Moreover, we propose that interference with the netrin-1 autocrine loop in malignant neuro-
blasts could represent an alternative therapeutic strategy, as disruption of this loop triggers in 
vitro NB cell death and inhibits NB metastasis in avian and mouse models.
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After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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UNC5H expression in stage 4S vs. other stage 4 NBs: 2.98-
fold, P < 0.007), suggesting UNC5H receptors as hallmarks 
of stage 4S NB. The UNC5H1 and UNC5H4, which show 
the highest messenger RNA (mRNA) expression, could also be 
seen at the protein level by immunohistochemistry (Fig. 1 D).
In an attempt to correlate netrin-1 up-regulation with the 
molecular signature of these tumors, we compared netrin-1 
up-regulation and DCC/UNC5H1 levels to the profile of 
gene expression performed in a small panel of nine stage 4 NBs 
(30). We failed to detect any correlation between netrin-1 up-
regulation or DCC/UNC5H1 levels with the molecular sig-
nature of apoptosis or invasion effectors (Fig. S1 D). Considering 
patients’ outcomes, although 38% of [1yr+] stage 4 NBs have 
selected up-regulation of netrin-1, this event failed to be sig-
nificantly associated with poor outcome in this aggressive form 
of the disease (unpublished data). Moreover no association be-
tween  netrin-1  up-regulation  and  MYCN  amplification 
(MNA) was detected (unpublished data). Thus, netrin-1 up-
regulation may be considered as an additional component of 
the genetic complexity that these tumors display.
Despite a largely favorable prognosis among infants with 
stage 4 NB (i.e, stage 4S and [1yr] stage 4) with no MNA, 
many succumb to the disease. Thus, we assessed whether ne-
trin-1 expression may serve as a prognostic marker for the in-
fants with stage 4 NB. As shown in Fig. 1 E, the overall survival 
of infants with stage 4S differed markedly based on whether 
the tumor displayed high levels of netrin-1 expression (netrin-
1 high) or low-level expression (netrin-1 low), with the ne-
trin-1 expression threshold being its median expression value 
in the 102 cases. Indeed, although 100% of the infants survived 
after 10 yr (including 1 MNA out of 17), when the NB 4S was 
netrin-1 low, the 5-yr overall survival was only 46% when the 
NB 4S was netrin-1 high (P = 0.0109). Furthermore, 43% of 
the non-MNA patients with high-level netrin-1 expression 
died. More generally, when a similar overall survival analysis 
was performed on all infants with stage 4 NB (i.e, stage 4S and 
[1yr] stage 4), a similar dichotomy was observed. Indeed, 5-yr 
overall survival was found to be 90% for the netrin-1–low infants 
yet only 48% for netrin-1–high infants (P = 0.032; Fig. 1 F). 
These data suggest that netrin-1 is a potential prognostic marker 
for aggressiveness in stage 4 NB diagnosed in infants. Whether 
or not it constitutes an independent prognostic marker of stage 
4 NB in neonates and infants deserves to be tested in a larger 
patient cohort. Nevertheless, these data indicate that a netrin-1 
threshold may turn as an alternative determinant for the bio-
logical behavior of stage 4 NB in infants, potentially suggesting 
its involvement in a cell death process of very early childhood 
neuroblasts, reminiscent of that operating during nervous sys-
tem development (31).
Netrin-1 high expression is not only detected in 38% of 
[1yr+] stage 4 and in poor outcome [1yr] stage 4 primary NB 
tumors but also in a fraction of NB cell lines mainly derived 
from stage 4 tumor material (Fig. 2 A and Fig. S2 A). Two   
human NB cell lines, IMR32 (netrin-1 high) and CLB-Ge2 
(netrin-1 low), were evaluated further. In spite of a marked dif-
ference in netrin-1 and DCC expression, the UNC5H levels 
the vast majority of human cancers (22, 23). This hypothesis 
also fits with the observation that UNC5H genes are down-
regulated in most colorectal tumors, hence suggesting that loss 
of UNC5H genes represents a selective advantage for tumor 
development (21, 24, 25). We have analyzed expression of ne-
trin-1 and its receptors in neuroblastoma (NB), the most fre-
quent extracranial solid tumor of early childhood. The aggressive 
and metastatic stage 4 NB displays three distinct clinical patterns 
at presentation and dissemination sites based on patients’ ages. 
Indeed, neonates and infants (<1 yr of age) with stage 4S and 
stage 4 without 4S features have an overall good prognosis, 
whereas stage 4 in children (>1 yr of age) shows a poor prog-
nosis. We describe in this paper that, rather than the loss of 
netrin-1 receptor expression, a large fraction of aggressive NBs 
has evolved to select a gain of ligand expression that apparently 
represents a similar selective growth advantage. We therefore 
propose to use disruption of this selective advantage as an anti-
cancer strategy in NB.
RESULTS
Netrin-1 is up-regulated in a large fraction  
of aggressive NB
We focused on stage 4 NB with a specific interest in compar-
ing netrin-1 and its receptors’ expression levels between the 
three distinct clinical patterns of stage 4, based on disease dis-
tribution and age of the patients (26). On the one hand, there 
are the neonates and infants (<1 yr of age) with stage 4S (2–5% 
of all NB) and the similarly young stage 4 without 4S features, 
hereafter termed [1yr] stage 4, who make up 10% of the NB 
population. On the other hand, there are the stage 4 children 
(>1 yr of age), comprising 45% of all NBs, who will hereafter 
be termed [1yr +] stage 4. These three clinical aspects of stage 
4 NB differ in their respective malignant behaviors and associ-
ated prognoses: good for stage 4S and [1yr ] stage 4 (5-yr 
event-free survival >80%), and dismal for [1yr +] stage 4 (5-yr 
event-free survival of 30%) despite intensive treatment in-
cluding high-dose chemotherapy and hematopoietic stem cell 
transplantation (27, 28).
We first analyzed the expression of netrin-1 and its de-
pendence receptors, DCC, UNC5H1, UNC5H2, UNC5H3, 
and UNC5H4, by quantitative RT-PCR (Q-RT-PCR) in a 
panel of 102 stage 4 NB tumors including 24 stage 4S and 12 
[1yr] stage 4. As shown in Fig. 1 A, netrin-1 is up-regulated 
in [1yr+] stage 4 as compared with both stage 4S (P < 0.05) 
and [1yr] stage 4 (P < 0.01). Similar results were obtained 
when comparing netrin-1 protein level by immunohisto-
chemistry (Fig. 1 B and quantification in Fig. S1 A). Interest-
ingly, netrin-1 is detected mainly in tumor cells and is barely 
detected in stroma cells (Fig. 1 B and Fig. S1 B). Conversely, 
netrin-1 dependence receptor expression analysis showed that 
DCC was only weakly expressed in the different stage 4 NB 
(Fig. S1 C) as reported (29), whereas UNC5H1, UNC5H2, 
UNC5H3, and UNC5H4 expression showed no significant dif-
ferences when comparing [1yr] versus [1yr+] stage 4 (Fig. 1 C). 
However, we observed that the different UNC5H receptors 
are up-regulated specifically in stage 4S (mean increase in JEM VOL. 206, April 13, 2009 
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production, we next performed netrin-1 immunohistochemis-
try on IMR32 and CLB-Ge2 cells. As shown in Fig. 2 D, a 
netrin-1–specific membrane staining was detected in a homo-
geneous pattern in IMR32 cells, whereas no specific staining 
was detected for CLB-Ge2 cells. Confocal analysis further con-
firmed the presence of netrin-1 at the cell membrane (Fig. 2 E 
are similar in IMR32 and CLB-Ge2 cells; UNC5H1, UNC5H3, 
and UNC5H4 show the highest expression (Fig. 2 B). Specifi-
cally, UNC5H1, UNC5H3, and UNC5H4 proteins could be 
detected at the plasma membrane by confocal analysis (Fig. 2 C). 
To test the hypothesis that the high netrin-1 mRNA levels de-
tected in IMR32 cells are associated with an autocrine netrin-1 
Figure 1.  Netrin-1 up-regulation is detected in aggressive NB. (A) Netrin-1 mRNA levels in 102 stage 4S (n = 24), [1yr ] stage 4 (n = 12), and 
[1yr+] stage 4 (n = 66) NBs measured by Q-RT-PCR. HPRT housekeeping gene was used as a control. Mean netrin-1 mRNA expression value for each sub-
group is indicated by an “m” value. Mean netrin-1 mRNA levels in stage 4S and [1yr] stage 4 were, respectively, compared with the mean netrin-1 de-
tected in [1yr+] stage 4. The data were statistically determined using Student’s t test compared with levels of [1yr+] stage 4. *, P < 0.05; **, P < 0.01. Each 
sample was assessed in two independent experiments. (B) Representative netrin-1 immunohistochemistry on one [1yr+] stage 4 and one stage 4S tumor. 
Insets show control without primary antibody. Bars, 50 µm. T, tumor cells; S, stromal cells. Netrin-1 antibody specificity is further shown in Fig. 2 D and 
Fig. S1 B. Immunohistochemistry was performed on four [1yr+] stage 4 and four stage 4S tumors. (C) Mean UNC5H mRNA levels in the different stage  
4 NBs. Q-RT-PCR using UNC5H1–4-specific primers was performed. Mean UNC5H1–4 mRNA levels in [1yr] stage 4 and [1yr+] stage 4 were, respectively, 
compared with the mean UNC5H1–4 levels detected in stage 4S. Error bars indicate SEM. The data were statistically determined using Student’s t test 
compared with levels of stage 4S. *, P < 0.05; **, P < 0.01. Samples were analyzed in duplicates for each gene. (D) Representative UNC5H1 and UNC5H4 
immunohistochemistries on [1yr+] stage 4 and stage 4S tumors. Insets show control without primary antibody. Bars, 50 µm. Immunohistochemistry was 
performed on four stage 4 [1yr+] and four stage 4S tumors. (E) Netrin-1 up-regulation is a marker of poor prognosis in stage 4S NB. Overall survival in a 
panel of 24 infants diagnosed with stage 4S NB with primary tumors showing either netrin-1–low (gray) or netrin-1–high (black) levels. The data was 
statistically determined using the Kaplan-Meier method. P-value is indicated. (F) Netrin-1 up-regulation is a marker of poor prognosis in infants with NB. 
Data are presented as in E, with a panel of 30 infants bearing NB.836 NETRIN-1 TARGETING IN NEUROBLASTOMA | Delloye-Bourgeois et al.
Figure 2.  Netrin-1 up-regulation is detected in NB cell lines. (A) Netrin-1 expression measured by Q-RT-PCR in a panel of 28 NB cell lines. HPRT 
housekeeping gene was used as a control. The netrin-1 level is indicated as follows: , not detectable; /+, barely detectable; + to ++++, moderate to 
very high expression. Mouse cell lines are in italics. Cell lines outlined and highlighted in grey are, respectively, netrin-1–low and netrin-1–high cell lines 
further used in the experiments. (B) Netrin-1 receptor expression in IMR32 and CLB-Ge2 cell lines. DCC/UNC5H Q-RT-PCR was performed on netrin-1–
expressing (IMR32) or netrin-1–low (CLB-Ge2) cells using specific primers. Ratio of netrin-1 and netrin-1 receptor expression to the HPRT housekeeping JEM VOL. 206, April 13, 2009 
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caspase-3 activity was measured in response to netrin-1 siRNA 
treatment. As shown in Fig. 3 D, although significant apoptotic 
cell death was detected upon netrin-1 siRNA treatment in 
IMR32 cells, no such effect was observed in CLB-Ge2 cells. 
A similar proapoptotic effect of the netrin-1 siRNA was ob-
served in CLB-VolMo cells, another netrin-1 high cell line 
(unpublished data).
Interference with netrin-1 triggers UNC5H-induced 
apoptosis in NB cells
As a second approach, we looked for a compound that could 
interfere with the netrin-1 ability to block DCC/UNC5H 
proapoptotic activity. We recently reported that the fifth fi-
bronectin type III domain of DCC (DCC-5Fbn; Fig. 4 A), 
which is located in the DCC ectodomain, interacts with   
netrin-1 and blocks the ability of netrin-1 to trigger multi-
merization of DCC and UNC5H receptors. Because mul-
timerization inhibits DCC or UNC5H-induced cell death 
(unpublished data), DCC-5Fbn antagonizes netrin-1 func-
tion, disrupting netrin-1–mediated inhibition of DCC/
UNC5H proapoptotic activity. Thus, DCC-5Fbn acts as a 
trap for netrin-1 survival function. As shown in Fig. 4 (B–D), 
the addition of DCC-5Fbn, but not the unrelated protein IL3R, 
triggered IMR32 apoptotic cell death as measured by trypan 
blue exclusion (Fig. 4 B), caspase-3 activity assay (Fig. 4 C), and 
terminal deoxynucleotidyl transferase–mediated dUTP-bio-
tin nick end labeling (TUNEL) staining (Fig. 4 D). This effect 
was specific for netrin-1 inhibition because DCC-5Fbn had 
no effect on CLB-Ge2 cells, and the addition of netrin-1 ulti-
mately reversed the DCC-5Fbn–induced IMR32 apoptotic 
cell death (Fig. 4, B–D). Similar results were obtained with 
the CLB-VolMo cells (Fig. S2 D). To determine whether the 
ability of DCC-5Fbn to kill NB cells is restricted to estab-
lished NB cell lines, a surgical biopsy from a tumor with high 
netrin-1 level (unpublished data) was semidissociated and fur-
ther  incubated  with  DCC-5Fbn.  As  shown  in  Fig.  4  E, 
DCC-5Fbn triggered cell death as measured by caspase-3 
activation, demonstrating that in vitro, disruption of the ne-
trin-1 autocrine loop is associated with NB cell death.
We next investigated whether netrin-1 autocrine expres-
sion in NB cells acts as a general cell survival factor, i.e., 
whether it has a trophic effect similar to that of neurotroph-
ins, or whether it specifically inhibits death induced by 
and Fig. S2 B). To further analyze whether netrin-1 is secreted 
from IMR32 cells, netrin-1 ELISA assay was used to detect ne-
trin-1 in the conditioned medium. As shown in Fig. 2 F, 11.7 
ng/ml netrin-1 was recovered from the conditioned medium 
of IMR32 cells, whereas no netrin-1 was detected from the 
conditioned medium of CLB-Ge2 cells. Thus, together these 
data suggest that the high netrin-1 content observed in aggres-
sive NB could result from an autocrine expression of netrin-1 
in NB cells.
As a first approach to apprehend the mechanisms leading to 
netrin-1 up-regulation in aggressive NB, we analyzed whether 
netrin-1 gene (NTN1) is amplified in IMR32 cells. As shown 
in Fig. 2 G, although MYCN was amplified both in IMR32 
and CLB-Ge2 cells compared with the NAGK control gene, 
the NTN1 gene was not found to be amplified in these two cell 
lines. We then analyzed whether the increase in netrin-1 ex-
pression could be caused by a differential netrin-1 promoter ac-
tivation. A luciferase reporter gene fused to netrin-1 promoter 
(32) was then transfected into IMR32 or CLB-Ge2 cells, and 
luciferase activity was reported to an internal control in each 
cell line. As shown in Fig. 2 H, netrin-1 promoter activity was 
13.8-fold higher in IMR32 cells than in CLB-Ge2 cells, thus 
supporting the view that netrin-1 up-regulation in NB is re-
lated to a gain in netrin-1 promoter activation.
Netrin-1 up-regulation is a selective advantage  
for NB cell survival
To investigate whether the netrin-1 autocrine expression ob-
served in IMR32 cells provides a selective advantage for sur-
vival, as would be expected from the dependence receptor 
theory, cell death was analyzed in response to the disruption of 
this autocrine loop. As a first approach, netrin-1 was down-reg-
ulated by RNA interference. As shown in Fig. 3 A, the addition 
of netrin-1 small interfering RNA (siRNA) to IMR32 cells was 
associated with a significant reduction in netrin-1 mRNA. This 
mRNA reduction was associated with a decrease of netrin-1 
protein as observed by immunohistochemistry (Fig. 3 B). Al-
though scramble siRNA failed to affect IMR32 cell survival, as 
measured by trypan blue exclusion, netrin-1 siRNA treatment 
was associated with IMR32 cell death (Fig. 3 C). In contrast, 
CLB-Ge2 cell survival was unaffected after netrin-1 siRNA 
treatment (Fig. 3 C). To determine whether this increase in cell 
death was in part caused by an increase in apoptotic cell death, 
gene is presented. (C) Confocal analysis of UNC5H1, UNC5H3, and UNC5H4 receptor immunostaining in human IMR32 cells. Left and right correspond to 
IMR32 cells transfected with scramble siRNA and specific siRNA UNC5H, respectively. A fluorescence intensity profile corresponding to the white dashed 
bar is presented under each panel. Bars, 10 µm. (D) Immunostaining on human IMR32 and CLB-Ge2 cell lines using netrin-1 antibody. Bottom insets show 
control without primary antibody. Top inset: antibody specificity was tested by adding human recombinant netrin-1. Bars, 50 µm. (E) Confocal analysis of 
netrin-1 immunostaining on IMR32 cells. A fluorescence intensity profile corresponding to the white dashed bar is presented below. Bar, 5 µm. (F) Quanti-
fication of netrin-1 protein secreted in IMR32 and CLB-Ge2 cells conditioned medium by sandwich ELISA assay. Quantification in ng/ml was made ac-
cording to a dose curve done with recombinant human netrin-1. Data are means of three independent experiments. Error bars indicate SEM. *, P < 0.05 
using a two-sided Mann-Whitney test compared with level in IMR32 cells. (G) Quantification of NTN1 and MYCN genomic DNA compared with control 
NAGK genomic DNA by PCR, using genomic DNA specific primers for each gene, in IMR32 and CLB-Ge2 cells. (H) Quantification of NTN1 promoter activ-
ity in IMR32 and CLB-Ge2 cells. Both cell lines were transfected with the vector pGL3-NetP-Luc encoding luciferase under the control of NTN1 promoter. 
Data presented are normalized on luciferase activity in cells transfected with pGL3 empty vector. Data are means of four independent experiments. Error 
bars indicate SEM. *, P < 0.05 using a two-sided Mann-Whitney test compared with levels in IMR32 cells.
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approach and, as shown in Fig. S3 A, this has no effect on 
netrin-1 siRNA-mediated IMR32 cell death. Thus, the 
netrin-1 autocrine loop probably blocks UNC5H-induced 
IMR32 cell death.
To more specifically address the identity of the UNC5H 
receptors involved in this cell death induction, we down-
regulated the expression of each UNC5H receptor individu-
ally (UNC5H1, UNC5H2, UNC5H3, or UNC5H4) by a 
siRNA approach (Fig. 5 C and Fig. S3 B) while inducing cell 
death using netrin-1 siRNA (Fig. S3 C). None of the single 
UNC5H siRNAs was sufficient to inhibit netrin-1 siRNA-
mediated IMR32 cell apoptosis, suggesting some redundancy 
in UNC5H-induced cell death (Fig. 5 D). However, when 
combinations of siRNAs were used, we observed that com-
bined silencing of the four UNC5H receptors was sufficient 
to fully inhibit the death triggered by netrin-1 autocrine loop 
disruption (Fig. 5 D), whereas the same combination of siR-
NAs had no effect on CLB-Ge2 cell survival (Fig. S3 D). The 
respective  importance  of  UNC5H  receptors  in  netrin-1 
siRNA-induced cell death was then assessed by the different 
combination of two or three siRNAs; the combination of 
UNC5H1, UNC5H3, and UNC5H4 siRNAs was the only 
one to fully block cell death (Fig. 5 E). Thus, in agreement 
with the level of UNC5H receptors expressed in IMR32 
cells, it appears that disruption of the netrin-1 autocrine sur-
vival loop triggers UNC5H-induced cell death. Moreover, 
netrin-1 dependence receptors. IMR32 cells were transfected 
with  either  a  dominant-negative  mutant  for  DCC  (DN-
DCC)  or  UNC5H  (DN-UNC5H)  proapoptotic  activity. 
These dominant-negative mutants of dependence receptors 
actually encode the intracellular domain of these receptors 
mutated in their caspase cleavage sites, and these mutants 
have been shown both in vitro and in vivo to specifically 
block the proapoptotic activity of their wild-type counter-
parts (3, 9, 33). Cell death was then analyzed after netrin-1 
inhibition by siRNA. Although DN-DCC expression failed 
to inhibit netrin-1 siRNA-induced IMR32 cell death, ex-
pression of DN-UNC5H rendered IMR32 cells resistant to 
netrin-1 siRNA (Fig. 5 A). To more formally exclude the 
role in this death process of DCC or of altered forms of DCC 
that are known to be expressed in IMR32 cells (Fig. S2 C) 
(34), DCC was down-regulated by a siRNA approach and 
cell death was induced via netrin-1 siRNA. As shown in Fig. 
5 B, DCC siRNA had no effect on cell death per se and 
failed to inhibit netrin-1 siRNA-induced caspase-3 activa-
tion, strengthening the perception that in these cells DCC is 
not proapoptotic. Neogenin, a DCC homologue, has also 
been proposed to act as a receptor for netrin-1 (35, 36) even 
though this is still a matter of controversy (5, 37). We then 
investigated whether neogenin, which is expressed in IMR32 
cells (Fig. S2 C), could be implicated in the IMR32 cell death 
observed here. Neogenin was down-regulated by a siRNA 
Figure 3.  Down-regulation of netrin-1 autocrine loop by siRNA triggers NB tumor cell death. (A) Analysis of netrin-1 expression using Q-RT-PCR 
in nontransfected (control) IMR32 cell line or 24 h after transfection with scramble siRNA (siRNA scr.) or with netrin-1 siRNA (siRNA net.). Data are means 
of three independent experiments. Error bars indicate SEM. *, P < 0.05 using a two-sided Mann-Whitney test compared with levels in control.  
(B) Immunostaining on IMR32 cell line using netrin-1 antibody in the absence of transfection (control) or 24 h after transfection with scramble siRNA or 
netrin-1 siRNA. Note that the general caspase inhibitor z-VAD-fmk was added to avoid cell death induced by netrin-1 siRNA. Insets show control without 
primary antibody. Bars, 50 µm. (C and D) Cell death induction in IMR32 and CLB-Ge2 cell lines was quantified in nontransfected cells (control) or after 
transfection with either scramble siRNA or netrin-1 siRNA using trypan blue exclusion assay (C) or relative caspase-3 activity assay (D). Data are means of four 
independent experiments. In C and D, error bars indicate SEM. *, P < 0.05 calculated using a two-sided Mann-Whitney test compared with level of control.JEM VOL. 206, April 13, 2009 
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vation is not a result of cell death but is specifically engaged by 
UNC5H after netrin-1 inhibition (unpublished data).
Interference with netrin-1 inhibits NB progression  
and dissemination
We next assessed whether in vivo modulation of netrin-1 
could be used to limit/inhibit NB progression and dissemina-
tion. An elegant chicken model has been developed in which 
graft of NB cells in the chorioallantoic membrane (CAM) of 
10-d-old chick embryos recapitulates both tumor growth at a 
primary site, i.e., within the CAM, and tumor invasion and dis-
semination at a secondary site, metastasis to the lung (Fig. 6 A). 
In a first approach, IMR32 or CLB-Ge2 cells were loaded in 
UNC5H1, UNC5H3, and UNC5H4 are the receptors in-
volved in this proapoptotic effect.
Furthermore,  in  IMR32  cells,  the  proapoptotic  serine 
threonine kinase DAP kinase (DAPK), which is shown to be 
required for UNC5H-induced cell death, exhibited a loss of 
its inhibitory autophosphorylation (38) upon DCC-5Fbn 
treatment (Fig. 5 F) or netrin-1 siRNA transfection (Fig. 5 G). 
Accordingly,  autophosphorylation  was  restored  by  a  treat-
ment with excess netrin-1 or by a combination of UNC5H1, 
UNC5H3, and UNC5H4 siRNAs. Moreover, the transfec-
tion of the antiapoptotic protein BCL-2 was sufficient to in-
hibit netrin-1 siRNA-induced cell death but did not inhibit 
DAPK dephosphorylation, hence suggesting that DAPK acti-
Figure 4.  Disruption of netrin-1 autocrine loop by a decoy receptor fragment triggers NB tumor cell death. (A) Scheme representing netrin-1 
and its receptors DCC and UNC5H and the fifth fibronectin type III domain of DCC (DCC-5Fbn) used to induce cell death. The downstream effector DAPK 
implicated in UNC5H-induced cell death is also represented. (B–D) Quantitative analysis of cell death in IMR32 and CLB-Ge2 cell lines treated with 1 µg/
ml DCC-5Fbn, with or without addition of netrin-1 in excess (150 ng/ml) to reverse the effect of DCC-5Fbn. A negative control was also performed by 
adding an unrelated IL3R peptide produced in the same condition as DCC-5Fbn. Cell death was quantified by trypan blue exclusion assay (B) while apop-
tosis was monitored by measuring relative caspase-3 activity (C) or by TUNEL staining (D). Bars, 100 µm. In D, TUNEL staining was performed on three 
independent experiments. (E) Effect of DCC-5Fbn on fresh [1yr+] stage 4 NB. Tumoral cells were directly resuspended from the surgical punction and were 
plated for 24 h in presence of treatment. In B and C, data are means of six independent experiments. In E, data are means of two independent experi-
ments. Error bars indicate SEM. **, P < 0.01 calculated using a two-sided Mann-Whitney test compared with level of control.840 NETRIN-1 TARGETING IN NEUROBLASTOMA | Delloye-Bourgeois et al.
Figure 5.  NB tumor cell death occurs via UNC5H/DAPK proapoptotic signaling. (A) Quantification of cell death in IMR32 cells transfected with 
either a dominant-negative mutant for DCC proapoptotic activity (DN-DCC) or a dominant-negative mutant for UNC5H proapoptotic activity (DN-
UNC5H). Top: DN-DCC and DN-UNC5H proteins expression were analyzed by Western blot. Bottom: cell death was quantified by measuring relative cas-
pase-3 activity after scramble or netrin-1 siRNA transfection. SEM are indicated. Data are means of three independent experiments. *, P < 0.05 calculated 
using a two-sided Mann-Whitney test compared with level of control. (B) Quantification of cell death in IMR32 cells transfected with either a scramble 
siRNA or a netrin-1 siRNA together or not with a DCC siRNA. Top: DCC siRNA efficiency was verified by Western blotting on HEK293T cells transfected 
with pCR-hDCC together with scramble or DCC siRNA. Bottom: cell death was quantified by measuring relative caspase-3 activity. Data are means of 
three independent experiments. SEM are indicated. *, P < 0.05 calculated using a two-sided Mann-Whitney test compared with level of control. Similar 
results were obtained when neogenin or MYCN were down-regulated (Fig. S3 A). (C) Analysis of specificity and efficiency of each UNC5H siRNA by West-
ern blot in HEK293T cells transfected with UNC5H1, H2, H3, or H4 encoding vector together with each UNC5H siRNA. (D and E) Quantification of cell 
death in IMR32 cells transfected with either a scramble siRNA or a netrin-1 siRNA together with various combinations of UNC5H siRNA, i.e, one UNC5H 
(D) or two or four UNC5H (E). Apoptosis was monitored by measuring relative caspase-3 activity. The use of combined UNC5H1, UNC5H2, UNC5H3, and JEM VOL. 206, April 13, 2009 
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trin-1 autocrine loop inhibited or completely prevented the 
dissemination of netrin-1–expressing NB cells.
DISCUSSION
Together, the data obtained in the chick and mouse models 
described in the previous sections, in NB cell lines, and in the 
human pathology all support the view that a fraction of NB 
shows an autocrine production of netrin-1. This elevated ne-
trin-1 level likely confers a selective advantage acquired by the 
cancer cell to escape netrin-1 dependence receptor–induced 
apoptosis and, consequently, to survive in settings of environ-
mental absence or limitation of netrin-1. It is therefore interest-
ing to note that not only NB but also other neoplasms associated 
with poor prognosis, for example, metastatic breast cancer and 
pancreatic cancer, also express high levels of netrin-1 (33, 40), 
suggesting that netrin-1 up-regulation may be a common fea-
ture for several aggressive cancers. From a mechanistic point of 
view, in a large fraction of NB, this autocrine expression of ne-
trin-1 probably inhibits UNC5H-induced cell death. How-
ever, because DCC has been shown to display reduced 
expression in NB and because this reduction has been associ-
ated with NB aggressiveness in human NB (29), it is tempting 
to speculate that netrin-1 up-regulation can also, in some NB, 
inhibit  DCC-induced  apoptosis.  Interestingly,  this  netrin-1 
up-regulation appears to block a death signal involving the ser-
ine threonine DAPK, whose activity is regulated via its auto-
phosphorylation. It is therefore of interest to note that DAPK 
was described to be a negative regulator of tumor progression 
and, more specifically, of metastasis (41). Thus, it can be sug-
gested that a fraction of low netrin-1–expressing NB may have 
selected a loss of function of DAPK for survival. This would be 
compatible with the finding that metastasis in NB is associated 
with a loss of caspase-8, a selective advantage which provides 
survival to NB cells by inhibiting the proapoptotic signaling of 
the dependence receptor integrin 31 (42).
It is then interesting to wonder why such a large fraction of 
aggressive NBs have selected a gain of netrin-1 rather than a 
loss of the netrin-1 dependence receptor death pathways. A 
possible explanation is that netrin-1 expression not only con-
fers a gain in survival, but may also lead to enhancement of non-
apoptotic signaling mediated by netrin-1 receptors. Netrin-1 
was indeed shown to bind a complex that includes some inte-
grins (43). These integrins regulate cell migration and invasive-
ness and, thus, may play a role in cancer progression. Netrin-1 
was also proposed to play a role in angiogenesis, although 
whether netrin-1 is proangiogenic or antiangiogenic is contro-
versial (44–47) and this effect on angiogenesis may increase 
NB metastases development. It is also of interest to note that 
NB is a complex disease that originates from migrating neural 
crest cells. Netrin-1 up-regulation may then be implicated in 
10-d-old CAM and embryos were treated on days 11 and 14 
with PBS or DCC-5Fbn. 17-d-old chicks were then analyzed 
for  primary  tumor  growth  and  metastasis  to  the  lung.  As 
shown in Fig. 6 (B and C), specifically in CAMs grafted with 
IMR32 but not with CLB-Ge2 cells, DCC-5Fbn significantly 
reduced primary tumor size. This size reduction was associ-
ated with increased tumor apoptosis, as shown by an increased 
caspase-3 activity in the tumor lysate (Fig. 6 D). More impor-
tantly, DCC-5Fbn also reduced lung metastasis formation, as 
shown in Fig. 6 E. Similar results were obtained when CAM-
grafted embryos were treated with netrin-1 siRNA (unpub-
lished data). To next assess whether DCC-5Fbn could also 
induce the regression of metastatic lesions, IMR32 cells were 
CAM grafted and DCC-5Fbn (or PBS) treatment started after 
metastasis to the lung is known to occur, i.e., treatments were 
performed on days 14 and 15 because pulmonary metastases 
are routinely detectable at day 13. As shown in Fig. 6 F, pul-
monary metastases were markedly reduced, suggesting that 
DCC-5Fbn not only inhibits tumor dissemination but also 
induces regression of metastatic lesions at the secondary site.
As a second in vivo approach, we used the IGR-N-91 
model derived from a BM metastasis of human MYCN-ampli-
fied stage 4 NB. When subcutaneously xenografted into nude 
mice, IGR-N-91 cells gave rise to different tumor cell lines de-
rived from the nude mouse primary tumor xenograft (PTX) or 
from disseminated metastatic foci into BM, blood, and myocar-
dium (Myoc) of the animal (39). It is of interest that although 
the parental IGR-N-91 and the cell line derived from the PTX 
show no or very low netrin-1 expression, the different cell lines 
derived from secondary localizations showed a marked expres-
sion of netrin-1 both at the RNA level (Fig. 7 A) and at the 
protein level (Fig. 7 B). When cell death was investigated in 
these different cell lines upon treatment with DCC-5Fbn, a di-
rect correlation was observed between the level of netrin-1 and 
cell susceptibility to DCC-5Fbn (Fig. 7 C). Specifically, al-
though PTX cells failed to undergo cell death upon DCC-
5Fbn treatment, this treatment triggered netrin-1–high Myoc 
cell death (Fig. 7 C). This observation supports the overall view 
that gaining netrin-1 dependence receptor resistance, via an au-
tocrine netrin-1 expression in the case of the IGR-N-91 model, 
likely promotes NB tumor cell survival outside of the primary 
tumor site. To test whether this netrin-1 expression may then 
be used as a target to inhibit metastasis in vivo, Myoc and PTX 
cells were injected intravenously into nude mice and lung colo-
nization was quantitated after daily intraperitoneal treatment 
with PBS or DCC-5Fbn. Although lung colonization was not 
reduced upon DCC-5Fbn treatment in PTX-injected mice 
(not depicted), a significant decrease in lung colonization was 
detected in DCC-5Fbn–treated Myoc-injected mice (Fig. 7 D). 
Thus, in both chick and mouse models, disruption of the ne-
UNC5H4 or UNC5H1, UNC5H3, and UNC5H4 siRNAs, leading to the absence of death induced by netrin-1 siRNA, are presented in gray. Data are means of 
three independent experiments. Error bars indicate SEM. *, P < 0.05 calculated using a two-sided Mann-Whitney test compared with level of control.  
(F and G) Immunodetection of phosphorylated DAPK (P-DAPK) in IMR32 cells either treated with DCC-5Fbn (F) or transfected with netrin-1 siRNA alone 
or with UNC5H1, H3, and H4 siRNAs (G). In F and G, immunodetection was performed on three independent experiments.
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which metastases are found, one may wonder about the 
implication of netrin-1 produced in the normal tissues in 
which the tumor cells spread, and this would be interesting 
to explore. In particular, it would be interesting to evaluate 
whether, according to the classical “seed and soil” theory 
for metastasis (for review see reference 18), netrin-1 ex-
pression in specific tissues may favor metastasis develop-
ment more specifically in these tissues. It is also intriguing 
the main function played by netrin-1 during nervous system 
development that is neuronal navigation. Along this line, ne-
trin-1 and DCC have been shown to play an important role 
during neural crest cell migration (48), and it is then tempting 
to suggest that the gain in netrin-1 expression also promotes 
NB cell migration.
As different types of stage 4 NBs are distinguished, not 
only by the age of the children but also by the tissues in 
Figure 6.  Disruption of netrin-1 autocrine loop inhibits NB progression and dissemination in a chick model. (A) Schematic representation of 
the experimental chick model. IMR32 or CLB-Ge2 cells were grafted in CAM at day 10 and DCC-5Fbn or PBS was injected on days 11 and 14. Tumors and 
lungs were harvested on day 17. (B–D) Effect of DCC-5Fbn on primary tumor growth and apoptosis. (B) Representative images of IMR32 (top) or CLB-Ge2 
(bottom) primary tumors formed on CAM treated either with DCC-5Fbn (right) or PBS (left). Bars, 2 mm. (C) Quantitative analysis showing the mean pri-
mary tumor size. (D) Caspase-3 activity was determined in the primary tumor lysates from DCC-5Fbn/PBS-treated IMR32 or CLB-Ge2–grafted embryos. 
(E) Effect of DCC-5Fbn on lung metastasis. Percentage of embryos with lungs invaded by human IMR32 or CLB-Ge2 cells after two injections (days 11 and 
14) of either DCC-5Fbn or PBS was performed as described in the Materials and methods. (F) Effect of DCC-5Fbn on lung metastasis regression. Quantifi-
cation of lung metastasis in embryos CAM grafted with IMR32 cells and treated after metastasis formation (days 14 and 15) with DCC-5Fn or PBS. The 
number of embryos studied in each condition is indicated above the graphs and results are from three independent experiments. In C–F, errors bars indi-
cate SEM. C–F: *, P < 0.05; **, P < 0.005 calculated using a two-sided Mann-Whitney test compared with level of control. E: **, P < 0.005 calculated  
using a Chi-squared test.JEM VOL. 206, April 13, 2009 
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The observation that low levels of netrin-1 in NB corre-
late with good outcome is of clinical interest, in particular in 
NB diagnosed in neonates and infants. Indeed, low netrin-1 
expression predicts long-term survival in infants (100% in 4S 
stage and 90% in infants in general) in a type of pathology in 
which therapeutic management is highly dependent on pre-
sentation and MNA (50, 51). This is particularly true with 
to note that others have shown that in some particular cell 
lines, netrin-1 is able to promote apoptosis rather than in-
hibit apoptosis (49), so that the view of netrin-1 up-regula-
tion being only a survival-selective advantage to block 
apoptosis via dependence receptors is probably only part of 
the overall regulatory mechanisms that links NB, netrin-1, 
and its receptors.
Figure 7.  Disruption of netrin-1 autocrine loop inhibits NB dissemination in a mouse model. (A) Analysis of netrin-1 expression using Q-RT-PCR 
in IGR-N-91 cell line and the IGR-N-91–derived cell lines PTX , BM, Blood, and Myoc. Note that although PTX cells fail to express netrin-1, netrin-1 mRNA 
is highly expressed in Myoc cells. (B) Immunostaining on IGR-N-91 cells and the different derived cell lines PTX, BM, Blood, or Myoc using netrin-1 anti-
body. Bar, 50 µm. (C) Cell death was quantified in IGR-N-91, PTX, BM, Blood, or Myoc cell lines treated or not with DCC-5Fbn, with or without addition of 
netrin-1 in excess to reverse the effect of DCC-5Fbn. A negative control was also performed by adding an unrelated IL3R peptide produced in the same 
condition as DCC-5Fbn. Data are means of three independent experiments. Errors bars indicate SEM. *, P < 0.05, calculated using a two-sided Mann-
Whitney test compared with level of control. (D) Quantification of lung colonization in PTX or Myoc cells in i.v injected mice treated with PBS or DCC-
5Fbn for 22 d. Quantification was performed as described in the Materials and methods. Large bars indicate the median values for both groups. P-value 
was calculated using a two-sided Mann-Whitney test compared with level of control.844 NETRIN-1 TARGETING IN NEUROBLASTOMA | Delloye-Bourgeois et al.
BamH1 DNA fragment generated by PCR using pDCC-CMV-S as a tem-
plate. DCC-5Fbn production was performed using a standard procedure. In 
brief, BL21 cells were forced to express DCC-5Fbn in response to imidazole, 
and the BL21 lysate was subjected to affinity chromatography using FLAG-
Sepharose (Sigma-Aldrich). A peptide corresponding to the ectodomain of 
IL3R was produced in the same conditions and used as a control. For cell cul-
ture use, netrin-1, DCC, and neogenin siRNAs (Santa Cruz Biotechnology, 
Inc.)  were  designed  as  a  pool  of  three  target-specific  20–25-nt  siRNAs. 
UNC5H1, UNC5H2, UNCH3, and UNC5H4 siRNAs were designed by 
Sigma-Aldrich. MYCN siRNA was designed by Thermo Fisher Scientific.
Cell death assays. 2 × 105 cells were grown in serum-poor medium and 
were treated (or not) with 1 µg/ml DCC-5Fbn or transfected with siRNA 
using Lipofectamine 2000. Cell death was analyzed using trypan blue stain-
ing procedures as previously described (1). The extent of cell death is pre-
sented as the percentage of trypan blue–positive cells in the different cell 
populations. Apoptosis was monitored by measuring caspase-3 activity as 
described previously (1) using the Caspase 3/CPP32 Fluorimetric Assay kit 
(Gentaur). For detection of DNA fragmentation, treated cells were cyto-
spun, and TUNEL was performed with 300 U/ml TUNEL enzyme and   
6 µM biotinylated dUTP (Roche) as previously described (53).
Q-RT-PCR.  To  assay  netrin-1,  DCC,  and  UNC5H  receptor  expres-
sion in NB samples, total RNA was extracted from histologically quali-
fied tumor biopsies (>60% immature neuroblasts) using the NucleoSpin 
RNAII kit (Macherey-Nagel), and 200 ng were reverse transcribed using 
1U Superscript II reverse transcription (Invitrogen), 1U RNase inhibitor 
(Roche), and 250 ng of random hexamer (Roche). Total RNA was ex-
tracted from mouse and human cell lines using the NucleoSpin RNAII 
kit and 1 µg was reverse transcribed using the iScript cDNA Synthesis kit 
(Bio-Rad Laboratories). Real-time Q-RT-PCR was performed on a Light-
Cycler 2.0 apparatus (Roche) using the LightCycler FastStart DNA Master 
SYBER Green I kit (Roche). Reaction conditions for all optimal amplifi-
cations, as well as primer selection for murine and human netrin-1, DCC, 
and UNC5H1-4, were determined as already described. The ubiquitously 
expressed human HPRT genes showing the least variability in expression 
in NB was used as an internal control (54). The sequences of the prim-
ers are the following: NTN1, 5-TGCAAGAAGGACTATGCCGTC-3’ 
and 5-GCTCGTGCCCTGCTTATACAC-3; UNC5H1, 5-CATCAC-
CAAGGACACAAGGTTTGC-3 and 5-GGCTGGAAATTATCTTCT-
GCCGAA-3;  UNC5H2,  5-GGGCTGGAGGATTACTGGTG-3  and 
5-TGCAGGAGAACCTCATGGTC-3; UNC5H3, 5-GCAAATTGCT-
GGCTAAATATCAGGAA-3 and 5-GCTCCACTGTGTTCAGGCTA-
AATCTT-3; UNC5H4, 5-GGTGAACCCAGCCTCCAGTCAG-3 and 
5-CTTCCACTGACATCACTTCCTCCC-3; DCC, 5-AGCCAAT-
GGGAAAATTACTGCTTAC-3 and 5-AGGTTGAGATCCATGATT-
TGATGAG-3; and HPRT, 5-TGACACTGGCAAAACAATGCA-3 
and 5-GGTCCTTTTCACCAGCAAGCT-3.
Genomic DNA quantification. Genomic DNA from IMR32 and CLB-
Ge2 cells was extracted with the NucleoSpin Tissue kit (Macherey-Nagel). 
50 ng of genomic DNA was used to perform quantitative PCR using prim-
ers specific to NTN1 and MYCN genomic sequences. Real-time quantita-
tive PCR was performed on a LightCycler 2.0 apparatus using the Light 
Cycler FastStart DNA Master SYBER Green I kit. NAGK (the N-acetyl-
glucosamine kinase gene), which is located on chromosome 2 similarly to 
the MYCN gene but separated from the MYCN amplicon, was used as an 
internal control gene to determine the gene dosage (55). For each pair of 
primers, genomic DNA amplification was assessed by polymerase activation 
at 95°C for 10 min, followed by 35 cycles at 95°C for 10 s, 65°C for 30 s, 
and 72°C for 10 s. The sequences of the primers are the following: NTN1, 
5-CTGTGTCCCCCACTTGTTCT-3 and 5-CCATGAACCCCAC-
TGACTCT-3;  MYCN,  5-GTGCTCTCCAATTCTCGCCT-3  and 
5-GATGGCCTAGAGGAGGGCT-3; and NAGK, 5-TGGGCAGA-
CACATCGTAGCA-3 and 5-CACCTTCACTCCCACCTCAAC-3.
stage 4S infants who receive no (or minimal) treatment based 
on the lack of MNA, even though current statistics show that 
1 in 10 of these infants will eventually die of NB. In this pa-
per, we propose that determination of low netrin-1 level 
confirms a good prognosis for these infants without therapy, 
whereas the infants with high netrin-1 expression should be 
considered for more intensive treatment. Regarding infants 
or children with high netrin-1–expressing NB tumors, an al-
ternative or supplementary targeted treatment based on dis-
ruption of the netrin-1 autocrine survival loop may improve 
standard high-dose chemotherapy regimen efficiency. We 
propose that a treatment based on inhibition of the interac-
tion between netrin-1 and its dependence receptors, or inhi-
bition of the ability of netrin-1 to multimerize its receptors, 
could potentially improve the survival of a large fraction of 
the patients suffering from aggressive NB. Moreover, it is in-
teresting to note that no correlation between netrin-1 up-
regulation and molecular signature of apoptosis and invasion 
was observed in NB tumors (Fig. S1 D), strengthening the 
case for netrin-1 as an original target for NB. Future preclini-
cal and clinical studies should assess whether such therapeutic 
strategies, which could include small molecules (drugs), 
monoclonal antibodies, or the DCC-5Fbn recombinant pro-
tein presented in this paper, used alone or in combination 
with standard chemotherapy, could be of therapeutic benefit 
for infants and children with NB.
MATERIALS AND METHODS
Cell lines, transfection procedure, and reagents. Human NB cell lines 
were obtained from the tumor banks at Centre Léon Bérard and at Institut 
Gustave Roussy. More specifically, IMR32 and CLB-Ge2 cell lines were cul-
tured in RPMI 1640 GlutaMAX medium (Invitrogen) containing 10% FBS. 
IGR-N-91 cell line and its derivatives, as well as HEK293T cells, were cul-
tured in DME medium (Invitrogen) containing 10% FBS. Cell lines were 
transfected using Lipofectamine 2000 reagent (Invitrogen) for siRNA or Lipo-
fectamine Plus reagent (Invitrogen) for plasmids. Netrin-1 was obtained from 
Axxora and was used at a concentration of 150 ng/ml in all in vitro assays.
Human NB tumor samples and biological annotations. According to 
parental consent, surgical human NB tumor material was immediately fro-
zen. Material and annotations were obtained from the Biological Resources 
Centers of both national referent Institutions for NB treatment (Centre Léon 
Bérard and at Institut Gustave Roussy). Protocols using human material 
were approved by the local ethics Committees of Lyon University and Paris 
XI University. MYCN genomic content was assessed on histologically qual-
ified tumors as previously described (52). For immunohistochemistries, 5-
µm sections were prepared and frozen at 80°C.
Plasmid constructs, siRNA, and DCC-5Fbn production. The domi-
nant-negative mutant for UNC5H and DCC (pCR-UNC5H2-IC-D412N 
and pCR-DCC-IC-D1290N, respectively) and the plasmids encoding Neo-
genin  (pCDNA3-Neogenin)  and  UNC5H1  (pCDNA3.1-UNC5H1-HA) 
have been previously described (1, 2, 5). The plasmids encoding UNC5H2 
(pCDNA3.1-UNC5B-HA),  UNC5H3  (pCDNA3-UNC5C-HA),  and 
UNC5H4 (pCAG3-hU5H4-His) were gifts from H. Arakawa (National Can-
cer Institute, Tokyo, Japan), M. Tessier-Lavigne (Genentech, San Francisco, 
CA), K.L. Guan (University of Michigan, Ann Arbor, MI), and N. Yamamoto 
(Osaka University, Osaka, Japan). Human netrin-1–encoding plasmid (peak8-
hNTN1-His) was obtained from D.E. Bredesen (The Buck Institute for Age 
Research, Novato, CA). Ps974-DCC-5Fbn allowing bacterial expression of 
the fifth fibronectin type III domain of DCC was obtained by inserting a Pst1–JEM VOL. 206, April 13, 2009 
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determine the threshold between NB cell–invaded and –noninvaded lungs. To 
monitor apoptosis in primary tumors, primary tumors and surrounding CAM 
were resected and broken up in lysis buffer and caspase-3 activity was measured 
using the Caspase 3/CPP32 Fluorimetric Assay kit.
NB metastasis in nude mice. 7-wk-old (20–22 g body weight) female athy-
mic nu/nu mice were obtained from Charles River Laboratories. The mice 
were housed in sterilized filter-topped cages and maintained in a pathogen-free 
animal facility. IGR-N-91–derived PTX and Myoc cell lines were implanted by 
i.v. injection of 106 cells in 130 µl of PBS into a tail vein (day 0). 20 µg DCC-
5Fbn or PBS with equal volume was i.p. injected daily during 22 d. Lungs were 
harvested on day 23. Lung genomic DNA was extracted with the NucleoSpin 
Tissue kit, and quantification of human tumor cells in lungs was done by PCR-
based detection of the human Alu sequence using the primers 5-CACCTGTA-
ATCCCAGCACTTT-3 (sense) and 5-CCCAGGCTGGAGTGCAGT-3 
(antisense), using 25 ng of genomic DNA as previously described (56). PCR was 
performed under the following conditions: 95°C for 2 min, 30 cycles at 95°C 
for 30 s, 65°C for 20 s, and 72°C for 20 s. Quantification of human DNA in 
mice lungs was based on a standard curve using human genomic DNA isolated 
from PTX and Myoc cell lines.
Online supplemental material. Fig. S1 associates netrin-1 and DCC ex-
pression in NB tumors with their apoptosis and invasion molecular signatures 
obtained with microarrays. Fig. S2 presents netrin-1 mRNA and protein ex-
pression in NB cell lines and shows CLB-VolMo netrin-1–high cell line sen-
sitivity to DCC-5Fbn decoy fragment. In Fig. S3, MYCN and neogenin 
implication in netrin-1 siRNA-induced cell death is studied, and specificity 
and efficiency of UNC5H siRNAs are presented at the mRNA, protein, and 
cellular levels. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20082299/DC1.
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Research Laboratories), or an Alexa 488 donkey anti–goat antibody (Invitrogen), 
respectively. For tumor slides, netrin-1 and UNC5H4 signals were amplified us-
ing biotinyl-tyramide (TSA; Thermo Fisher Scientific) and Alexa 488–streptavi-
din (Invitrogen). Nuclei were visualized with Hoechst staining. Densitometric 
value corresponding to netrin-1 signal was quantified with AxioVision Release 
4.6 software. Immunoblots were performed as already described using anti–
phospho-DAPK and anti-DAPK (Sigma-Aldrich) (38), anti-DCC (1:500; Santa 
Cruz Biotechnology, Inc.), anti-neogenin (1:500; Santa Cruz Biotechnology, 
Inc.), anti-HA (1:7,500; Sigma-Aldrich), anti-HIS (1:1,000; QIAGEN), anti-
MYCN (1:1000; BD), or anti--actin (1:1,000; Millipore) antibodies.
Netrin-1 ELISA assay. Detection of netrin-1 protein in IMR32 and CLB-
Ge2 cell culture medium was performed using a modified ELISA assay. In brief, 
96-well plates (Nunc-Immuno plate MaxiSorp; Thermo Fisher Scientific) were 
coated with 200 ng/well of purified recombinant extracellular domain of DCC 
(DCC-Ec-Fc). To minimize aspecific binding, each well was incubated with 
100 µl of blocking solution, containing 5% (wt/vol) BSA (Sigma-Aldrich) in 
0.05% PBS-Tween. 3 ml FBS free cell culture medium was added sequentially 
(300 µl/well) to coated 96-well plates and incubated for 1 h at 37°C. After three 
washes with 0.5% BSA/PBS, 100 µl of rat anti–netrin-1 antibody (diluted 1:500 
in blocking solution) was added to each well and incubated for 30 min at 37°C. 
After extensive washing, each well was incubated with 100 µl HRP-conjugated 
goat anti–rat antibody (1:1,000; Jackson ImmunoResearch Laboratories) for 30 
min at 37°C. After removal of unbound antibody by three washes in 0.5% BSA/
PBS, the plates were incubated for 5 min at room temperature with ECL West-
ern Blotting Substrate (Thermo Fisher Scientific). Luminescent signal was mea-
sured using a Luminoskan Ascent apparatus (Thermo Fisher Scientific).
Reporter assay. 105 cells were plated in 12-well plates and transfected with 
the firefly luciferase reporter under the control of the netrin-1 promoter 
(pGL3-NetP-Luc) or the pGL3 empty vector. All transfections were done in 
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ing the Luminoskan Ascent apparatus. As an internal control of transfection 
efficiency, the renilla luciferase-encoding plasmid (pRL-CMV; Promega) 
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Chicken model for NB progression and dissemination. 107 NB cells 
suspended in 40 µl of complete medium were seeded on 10-d-old chick CAM. 
10 µg DCC-5Fbn or the same PBS volume was injected in the tumor on days 
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injected under the same conditions as for DCC-5Fbn. On day 17, tumors were 
resected and the area was measured with AxioVision Release 4.6 software (Carl 
Zeiss, Inc.). To test the effect of DCC-5Fbn on metastasis regression, 3 µg 
DCC-5Fbn or PBS was injected on days 14 and 15 in a chorioallantoic ves-
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and genomic DNA was extracted with a NucleoSpin Tissue kit (Macherey-
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